A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the effectiveness of combination anti-HIV drug
therapy (with protease inhibitors [PIs] or without) in patients with early HIV infections.
This study also looks at whether a drug called interleukin-2 (IL-2) can boost the immune
system of these patients.
Doctors are not sure which anti-HIV drug combination is best to use in patients who have
early HIV infection and have never received anti-HIV treatment. PIs are anti-HIV drugs that
decrease viral load (level of HIV in the blood). However, PIs can cause serious side effects
in some patients. Doctors would like to know if a drug combination that does not contain a PI
is just as good as one that contains PIs.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)